Search Results

Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease.

Mainz Biomed N.V. announced a research collaboration with Microba Life Sciences, a precision microbiome company leveraging a world-leading technology platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases.

Microba Life Sciences Limited, a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.

Microba Life Sciences Limited is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba.

SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.

Microba Life Sciences Limited is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected.

Microba Life Sciences, a precision microbiome science company, and Ginkgo Bioworks, the leading horizontal platform for cell programming, announced a partnership to identify single-strain, live bacteria product candidates against autoimmune diseases.

Microba Life Sciences Limited is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia.

Leaders in precision gut microbiome science, Microba Life Sciences have demonstrated how their proprietary Microba Community Profiler compares to other metagenomic profilers, with the study published in Frontiers in Microbiology.

Microba Life Sciences, a precision microbiome science company, will showcase its Therapeutic Platform and Discovery Platform for the identification of novel microbial signatures at annual Europe summit.